Microtubule inhibitor-based antibody–drug conjugates for cancer therapy

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 2227-2236

  Klute, Kelsey ^a   Nackos, Eleni ^a   Tasaki, Shinsuke ^a   Nguyen, Daniel P ^a   Bander, Neil H ^a   Tagawa, Scott T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antibody drug conjugate; Microtubule inhibitor; Monoclonal antibody

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BRENTUXIMAB VEDOTIN; CAPECITABINE; CAPROMAB; GEMTUZUMAB OZOGAMICIN; LAPATINIB; MONOCLONAL ANTIBODY J591; PERTUZUMAB; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

BLOOD TOXICITY; BREAST CANCER; BREAST METASTASIS; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DISULFIDE BOND; DRUG APPROVAL; DRUG CONJUGATION; DRUG RESPONSE; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; DRUG TOLERABILITY; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; MICROTUBULE; PERIPHERAL NEUROPATHY; REVIEW; TREATMENT OUTCOME;

EID: 84919329870     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S46887     Document Type: Review

References (95)

1. Saleh MN, Sugarman S, Murray J, et al. Phase I trial of the anti-lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J Clin Oncol. 2000;18(11):2282–2292.
2. Tolcher AW, Sugarman S, Gelmon KA, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol. 1999;17(2):478–484.
3. Hall A. The cytoskeleton and cancer. Cancer Metastasis Rev. 2009; 28(1–2):5–14.
4. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9(10):790–803.
5. Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol. 2011;8(4):244–250.
6. Verhey KJ, Hammond JW. Traffic control: regulation of kinesin motors. Nat Rev Mol Cell Biol. 2009;10(11):765–777.
7. Giannakakou P, Sackett DL, Ward Y, Webster KR, Blagosklonny MV, Fojo T. P53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol. 2000;2(10):709–717.
8. Roth DM, Moseley GW, Glover D, Pouton CW, Jans DA. A microtubule-facilitated nuclear import pathway for cancer regulatory proteins. Traffic. 2007;8(6):673–686.
9. Carbonaro M, Escuin D, O'Brate A, Thadani-Mulero M, Giannakakou R Microtubules regulate hypoxia-inducible factor-1 alpha protein trafficking and activity: implications for taxane therapy. J Biol Chem. 2012;287(15):11859–11869.
10. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512.
11. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154.
12. Thadani-Mulero M, Nanus DM, Giannakakou P. Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Res. 2012;72(18):4611–4615.
13. Schwartz EL. Antivascular actions of microtubule-binding drugs. Clin Cancer Res. 2009;15(8):2594–2601.
14. Vincent L, Kermani P, Young LM, et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest. 2005;115(11):2992–3006.
15. Tozer GM, Prise VE, Wilson J, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 2001;61(17):6413–6422.
16. Leandro-Garcia LJ, Leskela S, Jara C, et al. Regulatory polymorphisms in beta-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res. 2012;18(16):4441–4448.
17. Millecamps S, Julien JR Axonal transport deficits and neurodegenerative diseases. Nat Rev Neurosci. 2013;14(3):161–176.
18. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 2006;66(8):4426–4433.
19. Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol. 2013;76(2):248–262.
20. Bander NH. Antibody-drug conjugate target selection: critical factors. Methods Mol Biol. 2013;1045:29–40.
21. Kovtun YV, Audette CA, Ye Y, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006;66(6):3214–3221.
22. Erickson HK, Widdison WC, Mayo MF, et al. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem. 2010;21(1):84–92.
23. Nolting B. Linker technologies for antibody-drug conjugates. Methods Mol Biol. 2013;1045:71–100.
24. Willner D, Trail PA, Hofstead SJ, et al. (6-maleimidocaproyl)hydrazone of doxorubicin: a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug Chem. 1993;4(6):521—527.
25. Hamann PR, Hinman LM, Beyer CF, et al. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. Bioconjug Chem. 2005;16(2):346–353.
26. Zhao PY, Wilhelm SD, Audette C, et al. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem. 2011;54(10):3606–3623.
27. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21(7):778–784.
28. Kellogg BA, Garrett L, Kovtun Y, et al. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem. 2011;22(4):717–727.
29. Tassone P, Gozzini A, Goldmacher V, et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 2004;64(13):4629–4636.
30. Al-Katib AM, Aboukameel A, Mohammad R, Bissery MC, Zuany-Amorim C. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma. Clin Cancer Res. 2009;15(12):4038–4045.
31. Sanderson RJ, Hering MA, James SF, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res. 2005;11(2 Pt l):843–852.
32. Doronina SO, Mendelsohn BA, Bovee TD, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006;17(1):114–124.
33. Petrylak D, Smith D, Appleman L, et al. A phase II trial of prostate-specific membrane antigen antibody drug conjugate in taxane-refractory metastatic castration-resistant prostate cancer. J Clin Oncol. 2014; 32(5s):5023.
34. Wang X, Ma D, Olson WC, Heston WD. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther. 2011;10(9):1728–1739.
35. Vaklavas C, Forero A. Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CRO11-vcMMAE). BioDrugs. 2014;28(3): 253–263.
36. Doronina SO, Bovee TD, Meyer DW, et al. Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug Chem. 2008;19(10):1960–1963.
37. Poison AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 2009;69(6):2358–2364.
38. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280–9290.
39. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490–1496.
40. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244–3254.
41. Petersdorf SH, Kopecky KJ, Slovak M, et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood. 2013;121(24):4854–4860.
42. Amiri-Kordestani L, Blumenthal GM, Xu QC, et al. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. Epub May 30, 2014.
43. de Claro RA, McGinn K, Kwitkowski V, et al. US food and drug administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res. 2012;18(21):5845–5849.
44. Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39–51.
45. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpressed HER2. N Engl J Med. 2001;344(11):783–792.
46. Baselga J, Norton L, Albaneil J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58(13): 2825–2831.
47. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 1990;5(7):953–962.
48. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998;16(2):462–469.
49. Carter P, Smith L, Ryan M. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer. 2004;11(4):659–687.
50. Ohlschlegel C, Zahel K, Kradolfer D, Hell M, Jochum W. HER2 genetic heterogeneity in breast carcinoma. J Clin Pathol. 2011;64(12): 1112–1116.
51. Yang YL, Fan Y, Lang RG, et al. Genetic heterogeneity of HER2 in breast cancer: Impact on HER2 testing and its clinicopathologic significance. Breast Cancer Res Treat. 2012;134(3):1095–1102.
52. Austin CD, De Maziere AM, Pisacane PI, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell. 2004;15(12):5268–5282.
53. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010;28(16): 2698–2704.
54. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19): 1783–1791.
55. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2): 109–119.
56. Hoffman-La Roche. A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE). Available from: http://clinicaltrials.gov/show/NCT01120184. NLM identifier: NCT01120184. Accessed September 5, 2014.
57. Hoffman-La Roche. A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received At Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA). Available from: http://clinicaltrials.gov/ct2/show/NCT01419197. NLM identifier: NCT0141919. Accessed September 5, 2014.
58. Dana-Farber Cancer Institute. T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial). Available from: http://clinicaltrials.gov/ct2/show/NCT01853748. NLM identifier: NCT01853748. Accessed September 5, 2014.
59. Hoffmann-La Roche. A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines As Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01966471. NLM identifier: NCT01966471. Accessed September 5, 2014.
60. Hoffmann-La Roche. A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE). Available from: http://clinicaltrials.gov/ct2/show/NCT01772472. NLM identifier: NCT01772472. Accessed September 5, 2014.
61. West German Study Group. A Prospective, Randomized Multicenter Open-Label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy Vs Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol. (ADAPT; T-DM1). Available from: http://clinicaltrials.gov/ct2/show/NCT01745965. NLM identifier: NCT01745965. Accessed September 5, 2014.
62. Genentech. A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00951665. NLM identifier: NCT00951665. Accessed September 5, 2014.
63. Swiss Group for Clinical Cancer Research. Trastuzumab and Pertuzumab Followed by T-DM1 in MBC. Available from: http://clinicaltrials.gov/ct2/show/NCT01835236. NLM identifier: NCT01835236. Accessed September 5, 2014.
64. Dieras VA phase Ib/II trial of trastuzumab-DM1 with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results. Poster presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 2010.
65. Barok M, Tanner M, Koninki K, Isola J. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett. 2011;306(2):171–179.
66. Hoffmann-La Roche. A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT01641939. NLM identifier: NCT01641939. Accessed September 5, 2014.
67. Horie R, Watanabe T. CD30: Expression and function in health and disease. Semin Immunol. 1998;10(6):457–470.
68. Falini B, Pileri S, Pizzolo G, et al. CD30 (ki-1) molecule: anew cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85(1):1–14.
69. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25(19): 2764–2769.
70. Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146(2):171–179.
71. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–1465.
72. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–1821.
73. Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18(1): 248–255.
74. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183–2189.
75. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–2196.
76. Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012;119(26):6379–6381.
77. Gopal AK, Ramchandren R, O'Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120(3):560–568.
78. Seattle Genetics, Inc. A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial). Available from: http://clinicaltrials.gov/show/NCT01100502. NLM identifier: NCT01100502. Accessed September 5, 2014.
79. Millennium Pharmaceuticals, Inc. Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma. Available from: http://clinicaltrials.gov/show/NCT01712490. NLM identifier: NCT01712490. Accessed September 5, 2014.
80. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81–85.
81. Sokoloff RL, Norton KC, Gasior CL, Marker KM, Grauer LS. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate. 2000;43(2): 150–157.
82. Ananias HJ, van den Heuvel MC, Helfrich W, de Jong IJ. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate. 2009;69(10):1101–1108.
83. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48(2):326–334.
84. Evans MJ, Smith-Jones PM, Wongvipat J, et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci USA. 2011;108(23):9578–9582.
85. Miyamoto DT, Lee RJ, Stott SL, et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2012;2(11):995–1003.
86. Haffner MC, Kronberger IE, Ross JS, et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol. 2009;40(12):1754–1761.
87. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57(17):3629–3634.
88. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. 2004;22(13): 2522–2531.
89. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 1771utetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23(21): 4591–4601.
90. Tagawa ST, Beitran H, Vallabhajosula S, et al. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer. 2010;116(Suppl 4):1075–1083.
91. Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(18):5182–5191.
92. Osborne JR, Akhtar NH, Vallabhajosula S, Anand A, Deh K, Tagawa ST. Prostate-specific membrane antigen-based imaging. Urol Oncol. 2013;31(2):144–154.
93. Henry MD, Wen S, Silva MD, Chandra S, Milton M, Worland PI A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 2004;64(21):7995–8001.
94. Galsky MD, Eisenberger M, Moore-Cooper S, et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol. 2008;26(13):2147–2154.
95. Milowsky MI, Galsky M, George DJ, et al. Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC). J Clin Oncol (Meeting Abstracts). 2006;24(Suppl 18):4500.